Postreperfusion myocardial technetium-99m–sestamibi defect corresponds to area at risk: Experimental results from an ischemia–reperfusion porcine model

Add time:08/29/2019    Source:sciencedirect.com

IntroductionTechnetium-99m–sestamibi (MIBI) is the most frequently used myocardial perfusion tracer in patients with ischemic heart disease. In patients with acute ST-elevation myocardial infarction, we previously found that the defect in myocardial MIBI uptake was the same in patients injected with MIBI before primary angioplasty and in patients injected immediately after successful treatment. Thus, reperfusion may not be followed by increased uptake of MIBI. Instead, the MIBI defect after reperfusion may reflect the area at risk (AAR) defined by MIBI injected before treatment. We intended to investigate whether myocardial imaging with MIBI administered after reperfusion reflects myocardial perfusion or rather the ischemic AAR.

We also recommend Trading Suppliers and Manufacturers of TECHNETIUM SESTAMIBI (cas 113720-90-4). Pls Click Website Link as below: cas 113720-90-4 suppliers

Prev:Clinical investigationRest technetium 99m-sestamibi tomoscintigraphy in hibernating myocardium
Next:International prospective evaluation of scintimammography with technetium-99m sestamibi: interim results)